A biotechnology company measuring protein-protein interaction affinity at scale with a yeast mating assay, and engineering medicines from that data.
A-Alpha Bio / NVIDIA
Released November 11, 2024
Antibody-antigen binding affinity prediction and sequence optimization, pre-trained on 7.5 million quantitative yeast-display affinity measurements.